There are currently 144 ongoing clinical trials involving Allergic Rhinitis
Of the 144 trials,49 trials are in Phase II
Furthermore, 32 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Allergic Rhinitis, a respiratory condition. The highest number of ongoing clinical trials involving Allergic Rhinitis is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions involved in Allergic Rhinitis-related drug trials.
Inmunotek SL: The leading ongoing Allergic Rhinitis related clinical trials sponsor
Inmunotek SL is the top sponsor for Allergic Rhinitis-related ongoing clinical trials.
Roxall Medizin GmbH, Guangdong Provincial Hospital of Traditional Chinese Medicine, and Karolinska Instituteare a few other notable sponsors involving Allergic Rhinitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Allergic Rhinitis
Omalizumab (Xolair, Bolstran), Fexofenadine hydrochloride (Telfast, Allegra, Allegra FX, Fexofenadine, Fexal, Fexotabs, Telfastin Allergo, Telfast BD, Telfast OD, Exallegra, Telfastin Urticaria), and Montelukast sodium (Singulair/ Lukair/ Kipres/ Viatine/ Montelukast/ Imvlo/ Sparadac/ Xaira/ Lukasm/ Montelukast Sodium Prasco) are among the key marketeddrugs involving Allergic Rhinitis.
Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa monoclonal antibody. It functions via Immunoglobulin E (IgE) Inhibitor mechanism of action. It is formulated as powder for solution and solution for subcutaneous route of administration. Omalizumab is used for the treatment of Allergic Rhinitis and several other indications including Chronic Urticaria Or Hives, Allergic Asthma, Nasal Polyps (Nasal Polyposis). It was first approved in 2002 and is marketed globally including the US, the UK, Australia, France, Germany, and Russia by several prominent companies including Genentech USA Inc, Novartis AG and Cipla Ltd.
Fexofenadine hydrochloride (Telfast, Allegra, Allegra FX, Fexofenadine, Fexal, Fexotabs, Telfastin Allergo, Telfast BD, Telfast OD, Exallegra, Telfastin Urticaria) is an antihistamine drug. It functions via Histamine H1 Receptor (HRH1) Antagonist mechanism of action. It is formulated as tablets, solution, film coated tablets, hard gelatin capsules and suspension for oral route of administration and injectable solution for intravenous route of administration. Fexofenadine hydrochloride was first approved in 1996 and is marketed globally including the US, the UK, Australia, France, Germany, and Russia by several prominent companies including Sanofi, Medley Industria Farmaceutica Ltda, and Opella Healthcare Belgium NV/SA.
United States of America
Ireland
United States of America
United States of America
Japan
United Kingdom
United States of America
United States of America
Australia
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer